Affiris Progresses Alzheimer's Vaccine to Phase II Clinical Testing

Affiris’ clinical Alzheimer's vaccine candidate AD02 has already progressed to phase II clinical testing. It may therefore be possible to confirm the efficacy of the vaccine as early as during 2012.

The start of this efficacy study comes five months after the completion of the corresponding phase I study. The company is active in several disease areas and is currently developing a total of twelve prospective products in all stages of the development pipeline up to clinical phase II.

The vaccine candidate will be used in a multicentre phase II clinical study in Austria and five other European countries. Clinical centres in Germany, France, the Czech Republic, Slovakia and Croatia are taking part in the study. A total of 420 patients will be recruited.